作者
Jehan Dupuis,Emmanuel Bachy,Franck Morschhauser,Guillaume Cartron,Noriko Fukuhara,Nicolas Daguindau,René-Olivier Casasnovas,Sylvia Snauwaert,Rémy Gressin,Christopher P. Fox,Francesco d’Amore,Philipp B. Staber,Olivier Tournilhac,Krimo Bouabdallah,Catherine Thieblemont,Marc André,Shinya Rai,Daisuke Ennishi,Argyrios Gkasiamis,Mitsufumi Nishio,Luc‐Matthieu Fornecker,Marie‐Hélène Delfau‐Larue,Nouhoum Sako,Sébastien Mulé,Laurence de Leval,Philippe Gaulard,Kunihiro Tsukasaki,François Lemonnier
摘要
Follicular helper T-cell lymphomas (TFHL) harbour frequent alterations in genes that regulate DNA methylation. Preliminary reports suggest that treatment with 5-azacitidine has clinical activity in patients with relapsed or refractory TFHL. We aimed to compare the oral form of azacitidine with investigator's choice standard therapy (ICT; ie, gemcitabine, bendamustine, or romidepsin) in patients with relapsed or refractory TFHL.